Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not too shabby a profit :)
Some heavy hitters today, wonder if they'll want to take it back over $1, to be back in compliance with the minimum PPS. Watching EOD closely.
We only do big boards here, thx for understanding.
Nice expression, gotta remember that one.
COOL: nHOD +23%
We only do big boards here, thanks for understanding.
Learnt that the hard way... after a while you start wondering why a stock stalls at that particular point, and you stop trading blind lol.
Watching the 3/5min charts for volume clues.
Think your AAPL calls doing pretty fine right now. :)
Agree, no newsletter needed here :)
GERN: +9%
Volume approaching yesterday's spikes.
That is indeed an A+ crystal ball :) Nice work, Donis.
100% gains seem to be becoming regular?
Volume says it all.
ISR: +33%
Bit erratic, but going.
AMZN seems to have lost its spirit, not really taking part in the fun. Abut time too, after that run.
ACUR: +50%
Heading for the 200wMA @ 3.864
OCLR +12% on gap up.
Past resistance on the new SPY push. Looks like they might start the deep Christmas green today - took 'em longer than I had expected.
BTW, CRM has also made a pretty big break, at last.
BIOF: +10%
Going hard now.
Not out of the woods yet, IMO. Got a resistance line @ 541.62, so far no breaking out above. Will depend on SPY, I guess.
SHZ over the 100MA.
ACUR going again
HUSA 130K shares have traded in PM so far
Could be another fun day.
Yeah, longs have got themselves a sweet morning.
Reports Positive Results for CDX-301 in Hematopoietic Cell Populations. Future Development Planned
http://www.streetinsider.com/Corporate+News/Celldex+(CLDX)+Reports+Positive+Results+for+CDX-301+in+Hematopoietic+Cell+Populations/7938373.html
NQ rejects accusations in Seeking Alpha article
Lol, the power of SA in full display?
NQ Mobile Inc. (NYSE: NQ) rejected as false allegations made in an article published on seekingalpha.com on December 10, 2012, written by an author named "FJE Research" who has admitted to holding a short position in the Company.
NQ Mobile strongly rejects these allegations and notes that FJE Research's commentary contains numerous inaccuracies and misleading speculations based on flawed arguments and illustrates a lack of understanding of the Company's business model. The Company also stands firm and ready to protect its reputation and reserves legal rights against any deliberately false accusation. The following statements clarify the key misleading areas contained in the Seeking Alpha Article:
Johnson Controls would consider bidding again for A123, WSJ reports
And the soap continues:
Johnson Controls (JCI) wants the government to look closely at Wanxiang Group’s bid for most assets of bankrupt A123 Systems (AONE), reports the Wall Street Journal. Johnson says it would consider bidding again for A123 if Wanxiang fails to secure regulatory approval.
SOMX to be acquired by Pernix Therapeutics
Pernix Therapeutics (PTX) and Somaxon Pharmaceuticals (SOMX) announced that they have entered into a definitive merger agreement for Pernix to acquire Somaxon in a stock-for-stock transaction with a total equity value of $25M. Under the terms of the agreement, which has been unanimously approved by the boards of directors of both companies, Somaxon stockholders will receive aggregate consideration equal to $25M in Pernix common stock. The number of shares of Pernix common stock to be issued to the stockholders of Somaxon will be based on the volume-weighted average price of Pernix's common stock over the 30 day period ending on the day immediately prior to the closing of the proposed merger, subject to limitations on the maximum and minimum number of shares of Pernix common stock issuable in the transaction based on a price range of $6.00-$9.00 per share.